TU2218, a TGFβ-RI and VEGFR2 dual inhibitor, with pembrolizumab in solid tumors 

Do-Youn Oh, MD, PhD, Seoul National University College of Medicine, Seoul, South Korea, comments on the first-in-human study (NCT05204862) of TU2218, a dual inhibitor of TGFβ type I receptor (ALK5) and VEGFR2, in combination with pembrolizumab. The study explored the safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. Results showed that TU2218 was well-tolerated both as monotherapy and in combination, with manageable treatment-related adverse events. The recommended Phase II (NCT05784688) dose of the combination was established, demonstrating potential efficacy and a manageable safety profile. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.